FDCC
TMDX icon

Foster Dykema Cabot & Co’s Transmedics TMDX Stock Holding History

Foster Dykema Cabot & Co’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-54
Closed -$5K – 388
2023
Q2 		$5K Buy
+54
New +$4.13K ﹤0.01% 308

Other funds holding TMDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Foster Dykema Cabot & Co's TMDX Position: Q3 2023 in Review

Foster Dykema Cabot & Co sold out of Transmedics (TMDX) in Q3 2023, closing a stake of 54 shares — an estimated $5K sold.

Foster Dykema Cabot & Co first reported a position in TMDX in Q2 2023 and held it in 1 quarter. The position peaked at $5K in Q2 2023. 221 funds tracked by Wall St. Rank hold TMDX as of Q3 2023.

  • Foster Dykema Cabot & Co reported no remaining Transmedics position as of Q3 2023 after selling out during the quarter.
  • Foster Dykema Cabot & Co sold 54 Transmedics shares in Q3 2023, an estimated $5K.
  • Foster Dykema Cabot & Co first reported a position in Transmedics in Q2 2023 and held it in 1 quarter.
  • Foster Dykema Cabot & Co's Transmedics position peaked at $5K in Q2 2023.
  • 221 funds tracked by Wall St. Rank held Transmedics as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.